Compare Ginkgo Bioworks Holdings Inc (DNA) vs Nasdaq Inc (NDAQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Nasdaq Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.1 (market cap $590.53M), while Nasdaq Inc trades at $90.86 (market cap $49.77B). The key difference: Nasdaq Inc is far larger — about 84.3× Ginkgo Bioworks Holdings Inc's market cap, and Nasdaq Inc pays a 1.27% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | NDAQ | |
|---|---|---|
Market Cap | $590.53M | $49.77B |
Sector | Health | Financials |
52-Week High | $16.14 | $100.98 |
52-Week Low | $5.48 | $76.85 |
Enterprise Value | $627.78M | $56.84B |
Dividend Yield | — | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
Nasdaq (NDAQ) trades at $89.21, up 1.28% with a bullish technical signal and strong earnings momentum, beating estimates for three consecutive quarters. The company reported robust 2025 revenue of $8.26 billion and net income of $1.79 billion, with a net margin of 23.03%. Recent news highlights include SK Hynix's Nasdaq debut and positive analyst coverage, with 61% of analysts rating it a buy.
Outlook remains positive given earnings consistency and a $105.60 consensus price target, but risks include high valuation multiples and debt levels. Cash flow volatility from investing and financing activities warrants monitoring, though operational strength supports growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →
